HYEX HEALTHY EXTRACTS INC.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1630176 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY66.9%
TTM net income YoY-87.1%
TTM EPS YoY—
Revenue 3-yr CAGR31.5%
Net income 3-yr CAGR—
Margins
Gross margin62.4%
Operating margin—
Net margin-36.7%
FCF margin—
EBITDA margin—
Returns
ROE-9.7%
ROA-7.5%
ROIC (approx.)—
Asset turnover0.21x
Leverage & solvency
Liabilities / assets34.0%
Debt / equity0.00x
Current ratio0.14x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.33x
Accruals ratio-10.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $4.51M | $3.11M | $2.49M | $2.25M | $1.68M |
| Cost of revenue | $2.09M | $1.20M | $864,055 | $879,951 | $981,520 |
| Gross profit | $2.42M | $1.91M | $1.62M | $1.37M | $695,078 |
| SG&A expense | $3.37M | $2.09M | $3.87M | $2.28M | $2.58M |
| Income tax | $0 | $0 | $0 | $0 | — |
| Net income | -$881,119 | -$840,671 | -$2.47M | -$983,121 | -$1.99M |
| EPS (diluted) | — | — | — | — | — |
| Banking | |||||
| Net interest income | -$210,279 | -$186,252 | -$176,948 | -$64,690 | -$52,453 |
| Balance sheet | |||||
| Cash & equivalents | $146,935 | $112,020 | $19,441 | $65,651 | $222,098 |
| Receivables | $187,750 | $11,003 | $30,440 | $105,794 | $133,340 |
| Inventory | $843,357 | $1.36M | $1.63M | $1.82M | $1.96M |
| Current assets | $1.33M | $1.66M | $1.90M | $2.04M | $2.31M |
| Goodwill | $21.12M | $193,260 | $193,260 | $193,260 | $193,260 |
| Intangibles | $4.23M | $3,445 | $3,306 | $5,501 | $1,035 |
| Total assets | $27.82M | $2.38M | $2.64M | $2.78M | $3.03M |
| Current liabilities | $1.76M | $1.34M | $1.68M | $902,788 | $558,841 |
| Total liabilities | $3.80M | $1.97M | $1.68M | $909,602 | $558,841 |
| Shareholders' equity | $24.03M | $410,377 | $954,590 | $1.87M | $2.47M |
| Shares outstanding | 16.87M | 2.99M | 2.95M | 2.88M | 338.38M |
| Cash flow statement | |||||
| Operating cash flow | $165,520 | $281,968 | -$415,749 | -$390,621 | -$901,298 |
| Capital expenditure | — | — | $0 | $7,987 | $0 |
| Free cash flow | — | — | -$415,749 | -$398,608 | -$901,298 |
| Investing cash flow | $56,301 | $0 | $0 | -$5,344 | -$96,004 |
| Financing cash flow | -$186,906 | -$189,389 | $369,539 | $239,518 | $1.16M |
| Depreciation & amortization | — | — | — | — | $5,100 |
| Stock-based compensation | — | — | — | $0 | $0 |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.